Nextech leads Vividion Therapeutics' Series B Financing
“Vividion reels in USD 82 million to push 3 lead programs towards the clinic” Fierce Biotech
Nextech co-leads Arrakis Therapeutics' Series B Financing together with venBio
“Arrakis Therapeutics Nabs USD 75 Million to Create a New Class of rSM Oncology Drugs” Biospace
Nextech joins Black Diamond Therapeutics' Series B Financing led by NEA
Black Diamond Therapeutics closes USD 85 Million Series B financing. Next-wave precision oncology company poised to advance multiple products into clinical development. Press Release
Nextech joins Peloton Therapeutics' Series E Crossover Round led by RA Capital
In addition to these three additions to the Fund V portfolio, Nextech also participated in Peloton Therapeutics’ February 2019 Series E financing on behalf of both Funds IV and V, bringing us to nine portfolio companies in the Fund V family. We are sad to see Peloton go so soon. It is such a thrill to work with teams translating ideas into compounds into drugs which transform the lives of patients in need. But we do believe it is a tremendous deal and that under Merck’s care, Peloton drugs will benefit more patients faster. And that is what this is all about.
Please feel free to contact us with any questions you may have.